4.5 Review

Insight in Hypoxia-Mimetic Agents as Potential Tools for Mesenchymal Stem Cell Priming in Regenerative Medicine

Journal

STEM CELLS INTERNATIONAL
Volume 2022, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2022/8775591

Keywords

-

Funding

  1. National Science Centre, Poland, under the Beethoven Programme [2016/23/G/ST2/04319]
  2. European Union [871124]

Ask authors/readers for more resources

Hypoxia-mimetic agents are new tools used in MSC priming and can replace hypoxia incubators. They can induce a hypoxic state and enhance cell proliferation, differentiation potential, migration potential, and neovascularization. In addition, hypoxia-mimetic agents can increase HIF-1α expression, alter metabolism, and enhance glycolysis. The use of hypoxia-mimetic agents in regenerative medicine is beneficial, especially in pretreating various diseases and promoting cardiac and cartilage regeneration. Understanding MSC priming is critical for evaluating safety procedures and clinical applications.
Hypoxia-mimetic agents are new potential tools in MSC priming instead of hypoxia incubators or chambers. Several pharmaceutical/chemical hypoxia-mimetic agents can be used to induce hypoxia in the tissues: deferoxamine (DFO), dimethyloxaloylglycine (DMOG), 2,4-dinitrophenol (DNP), cobalt chloride (CoCl2), and isoflurane (ISO). Hypoxia-mimetic agents can increase cell proliferation, preserve or enhance differentiation potential, increase migration potential, and induce neovascularization in a concentration- and stem cell source-dependent manner. Moreover, hypoxia-mimetic agents may increase HIF-1 alpha, changing the metabolism and enhancing glycolysis like hypoxia. So, there is clear evidence that treatment with hypoxia-mimetic agents is beneficial in regenerative medicine, preserving stem cell capacities. These agents are not studied so wildly as hypoxia but, considering the low cost and ease of use, are believed to find application as pretreatment of many diseases such as ischemic heart disease and myocardial fibrosis and promote cardiac and cartilage regeneration. The knowledge of MSC priming is critical in evaluating safety procedures and use in clinics. In this review, similarities and differences between hypoxia and hypoxia-mimetic agents in terms of their therapeutic efficiency are considered in detail. The advantages, challenges, and future perspectives in MSC priming with hypoxia mimetic agents are also discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available